Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".
Dermatol Ther (Heidelb)
; 14(3): 823-827, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38438784
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Dermatol Ther (Heidelb)
Year:
2024
Document type:
Article
Affiliation country:
Netherlands